Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats metastatic or locally advanced epithelioid sarcoma not eligible for complete…. Sold as Tazverik. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Tazemetostat Hydrobromide (sold as Tazverik), first approved Jan 23, 2020, with 0 new uses approved and 0 published complete response letters.
First approved: Jan 23, 2020
Applications: 2
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $25.1M
Orphan exclusivity until: Jun 18, 2027
First approved in Japan: Jun 23, 2021
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 17 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Tazverik, new ingredientA drug with a new active ingredient indicated for the treatment of relapsed or refractory EZH 2 gene mutation-positive follicular lymphoma (for use only if… · Eisai Co., Ltd. · Jun 23, 2021 · Review report
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
